Inovio could take malaria vaccine to human trials next year

08/15/2013 | American City Business Journals

Inovio Pharmaceuticals has announced that its SynCon DNA malaria vaccine elicited lasting antibody and T-cell immune responses in animal studies. A clinical study is expected to begin next year. "We have now generated strong immunology data with our malaria vaccine in nonhuman primates. We are excited to advance toward the very important health care goal of conquering malaria," Inovio President and CEO Dr. J. Joseph Kim said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC